A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Stage IV, non squamous NSCLC
• Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
• Have at least 1 measurable lesion per RECIST version 1.1
Locations
Other Locations
Georgia
ltd Institute of Clinical Oncology
RECRUITING
Tbilisi
Contact Information
Primary
Jaeyoung Jang
jaeyoung.jang@celltrion.com
+82 32 850 5769
Time Frame
Start Date: 2025-01-30
Estimated Completion Date: 2028-07
Participants
Target number of participants: 606
Treatments
Experimental: CT-P51
Active_comparator: EU-approved Keytruda
Related Therapeutic Areas
Sponsors
Leads: Celltrion